Interestingly enough, this observation is pertinent from a theoretical viewpoint; nonetheless, further studies with larger samples of different populations are required to elucidate the participation of IGFBP3 gene variants in NAFLD susceptibility. This evidence concerns the gene IGFBP3 and metabolic dysfunction-associated steatotic liver disease.